Monopar Therapeutics
MNPR
9 hedge funds and large institutions have $964K invested in Monopar Therapeutics in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.02% more ownership
Funds ownership: 0.3% → 0.32% (+0.02%)
10% less funds holding
Funds holding: 10 → 9 (-1)
13% less capital invested
Capital invested by funds: $1.1M → $964K (-$140K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$53.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.5K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.59K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5.25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $487K | +$12.5K | +484 | +2% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $189K | +$53.9K | +2,082 | +36% |
|
|
3
Northern Trust
Chicago,
Illinois
| $177K | +$1.22K | +47 | +0.7% |
|
|
4
BlackRock
New York
| $68K | -$5.59K | -216 | -7% |
|
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $20K | -$5.25K | -203 | -20% |
|
6
Morgan Stanley
New York
| $19K | – | – | – |
|
|
APA
7
American Portfolios Advisors
Holbrook,
New York
| $3.41K | – | – | – |
|
8
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
MNPR Hedge Fund Activity: Q3 2021 in Review
9 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2021, worth a combined $964K — down 13% from $1.1M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of MNPR and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $53.9K. The largest seller was BlackRock, cutting an estimated $5.59K.
- 9 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2021, down from 10 in Q2 2021.
- Funds reported $964K of Monopar Therapeutics stock for Q3 2021, down 13% quarter-over-quarter.
- 0 funds opened new Monopar Therapeutics positions in Q3 2021 and 1 closed out, a net change of -1 holder.
- The largest Monopar Therapeutics buyer in Q3 2021 was Geode Capital Management, an estimated $53.9K added.
- The largest Monopar Therapeutics seller in Q3 2021 was BlackRock, an estimated $5.59K sold.
Based on aggregated 13F filings for Q3 2021.